External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience ADPD 2024
Roche and Genentech at

ADPD 2024

March 05 - March 09
Lisbon, Portugal / Virtual (Hybrid)
adpd.kenes.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Mar 9 / Roche and Genentech
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures
This study embarks on a detailed analysis of cerebrospinal fluid (CSF) proteomics to unravel the molecular intricacies underlying semorinemab's impact in human studies. Utilizing an unbiased-data approach, "trial signatures'' were defined for each trial as the set of genes encoding proteins which were elevated under semorinemab treatment when compared to baseline. We assessed the signatures of each trial with single-cell RNAseq data to unravel the cellular origins to provide a comprehensive understanding of semorinemab's effects on the proteomic landscape. Analysis of the Lauriet and Tauriel CSF signature indicate that the Lauriet proteomic drug response is likely of microglia origin, including some contribution from proteins that are further elevated in Alzheimer’s-associated microglia. This endeavor aims to augment the clinical perspective with molecular insights, contributing to the ongoing discourse on tau-targeted therapies and their potential in the complex landscape of Alzheimer's disease.
Neuroscience Alzheimer Disease ADPD-2024

Sign up or login to unlock the full suite of MEDICALLY features
Mar 9 / Roche and Genentech
Rapid dose-dependent amyloid plaque depletion with trontinemab, a novel BrainshuttleTM antibody in development for the treatmetn of Alzheimer's disease
Trontinemab is currently being studied in the Brainshuttle™ AD study, a Phase Ib/IIa study assessing the safety, tolerability, PK and PD of trontinemab in participants with AD. This study investigates 4 different doses in an MAD setting for a treatment period of 7 months - with the option to expand the 2 most promising cohorts. Preliminary data from the highest dose cohort of 3.6mg/kg Q4W shows very fast and extensive amyloid plaque reduction after only 12 weeks of treatment, with 63% of participants reaching the amyloid positivity threshold. This represents a further acceleration compared to the 40% reported previously with the 1.8mg/kg cohort during the same period.
Neuroscience Alzheimer Disease ADPD-2024

Sign up or login to unlock the full suite of MEDICALLY features
Mar 9 / Roche and Genentech
A study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson’s disease (PADOVA): rationale, design and baseline data
PADOVA is a Phase IIb randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of prasinezumab for delaying motor progression in individuals with early PD on stale symptomatic therapy (L-dopa and MAOBi). Here, demographic and clinical baseline characteristics are presented, including a comparison between the MAOBi and L-dopa treated sub cohorts, as well as to the PASADENA population. One important aspect of this study is the novel primary endpoint, time to confirmed motor progression defined as 5 points on MDS-UPDRS Part III, chosen in order to assess change in the duration of the study.
Neuroscience Parkinson's Disease ADPD-2024
03:00 PM
Duration 24hrs Lisbon, Portugal
Modeling of Parkinson’s disease progression and impact of endpoint selection on probability of study success
Benjamin Ribba
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 24hrs Lisbon, Portugal
Poster: Slower progression of digital acoustic speech measures in early Parkinson’s Disease under prasinezumab during the first 52 weeks of the PASADENA study
Damian Kwasny
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 24hrs Lisbon, Portugal
Audio Recording: Slower progression of digital acoustic speech measures in early Parkinson’s Disease under prasinezumab during the first 52 weeks of the PASADENA study
Damian Kwasny
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 AM
Duration 15mins Virtual
Oral Presentation: Slower progression of digital acoustic speech measures in early Parkinson’s Disease under prasinezumab during the first 52 weeks of the PASADENA study
Damian Kwasny
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:45 PM
Duration 15mins Auditorium VIII
PASADENA long-term open-label extension continue to show reduced motor and functional progression in prasinezumab-treated individuals with early-stage Parkinson’s disease compared to a real-world data arm
Gennaro Pagano
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:20 PM
Duration 15mins Auditorium VI+VII
Performance of blood-based biomarker prescreening in the SKYLINE secondary prevention phase 3 study with gantenerumab
Tobias Bittner
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:00 AM
Duration 24hrs Lisbon, Portugal
SAMPLE STABILITY STUDY FOR THE ELECSYS® CSF II IMMUNOASSAYS AT 25 °C, 2-8 °C AND -15 TO -25°C
Manuilova E
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 24hrs Lisbon, Portugal
Cerebrospinal fluid biomarkers of NLRP3 pathway activation, neuroinflammation and neurodegeneration in Parkinson’s Disease: a meta-analysis
Bastian Zinnhardt
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:25 PM
Duration 15mins Auditorium VIII
A phase IIa study investigating a γ-secretase modulator in individuals at risk for or at the prodromal stage of Alzheimer's disease
Rosanna Tortelli
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:25 AM
Duration 15mins Auditorium I
Rapid dose-dependent amyloid plaque depletion with trontinemab, a novel BrainshuttleTM antibody in development for the treatmetn of Alzheimer's disease
Luka Kulic
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:40 PM
Duration 15mins Auditorium VIII
A study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson’s disease (PADOVA): rationale, design and baseline data
Tania Nikolcheva
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:25 PM
Duration 15mins Auditorium VII
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signatures
Felix L. Yeh
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.